The World Health Organization said on Friday it had suspended Gilead’s remdesivir from its so-called prequalification list, an official list of drugs used as a benchmark for supply by developing countries, after it released guidelines against its use in hospitalized COVID-19 patients.
“Yes, we suspended him from the PQ (prequalification list),” Tarik Jasarevic said in an email response to Reuters.
“The suspension is a signal to countries that the WHO, according to treatment guidelines, does not recommend countries to purchase the drug for COVID.”
He added that the WHO was unaware of international buyers supplying the drug to low- and middle-income countries.
(Except for the title, this story was not edited by The Bharat Express News staff and is posted Platforms.)